

# Toshio Tanaka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2677251/publications.pdf>

Version: 2024-02-01

49  
papers

7,577  
citations

172457

29  
h-index

206112

48  
g-index

50  
all docs

50  
docs citations

50  
times ranked

12799  
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 2014, 6, a016295-a016295.	5.5	2,943
2	Targeting Interleukin-6 Signaling in Clinic. Immunity, 2019, 50, 1007-1023.	14.3	570
3	Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy, 2016, 8, 959-970.	2.0	521
4	The Biology and Medical Implications of Interleukin-6. Cancer Immunology Research, 2014, 2, 288-294.	3.4	283
5	Therapeutic Targeting of the Interleukin-6 Receptor. Annual Review of Pharmacology and Toxicology, 2012, 52, 199-219.	9.4	240
6	Interleukin (IL-6) Immunotherapy. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028456.	5.5	223
7	IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22351-22356.	7.1	215
8	Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. International Journal of Biological Sciences, 2012, 8, 1227-1236.	6.4	200
9	Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis and Rheumatism, 1999, 42, 1635-1643.	6.7	195
10	The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology, 2010, 49, 2408-2412.	1.9	177
11	The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Review of Clinical Immunology, 2017, 13, 535-551.	3.0	166
12	Interleukin 6 and Rheumatoid Arthritis. BioMed Research International, 2014, 2014, 1-12.	1.9	149
13	Therapeutic uses of anti-interleukin-6 receptor antibody. International Immunology, 2015, 27, 21-29.	4.0	146
14	A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Seminars in Immunology, 2014, 26, 88-96.	5.6	144
15	Regulation of IL-6 in Immunity and Diseases. Advances in Experimental Medicine and Biology, 2016, 941, 79-88.	1.6	135
16	Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 344-354.	3.4	118
17	Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology, 2011, 50, 1344-1346.	1.9	115
18	The clinical importance of a cytokine network in the acute phase of sepsis. Scientific Reports, 2018, 8, 13995.	3.3	114

#	ARTICLE	IF	CITATIONS
19	Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab: Figure 1. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1164-1165.	0.9	79
20	Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2015, 67, 1481-1490.	5.6	79
21	Tocilizumab for the treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 843-854.	3.0	70
22	Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Arthritis and Rheumatism</i> , 2009, 61, 1762-1764.	6.7	69
23	A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Modern Rheumatology</i> , 2012, 22, 298-302.	1.8	64
24	Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. <i>Joint Bone Spine</i> , 2012, 79, 85-87.	1.6	58
25	Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica: Figure 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1075-1076.	2.0	55
26	Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. <i>Biologics: Targets and Therapy</i> , 2014, 8, 141.	3.2	45
27	Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions. <i>International Journal of Rheumatology</i> , 2012, 2012, 1-14.	1.6	40
28	Immunotherapeutic implication of IL-6 blockade. <i>Immunotherapy</i> , 2012, 4, 87-105.	2.0	35
29	Flavonoids for Allergic Diseases: Present Evidence and Future Perspective. <i>Current Pharmaceutical Design</i> , 2014, 20, 879-885.	1.9	30
30	Clinical Importance of a Cytokine Network in Major Burns. <i>Shock</i> , 2019, 51, 185-193.	2.1	29
31	Minimal influence of tocilizumab on IFN- $\gamma$ synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133.	1.8	25
32	Clonal evolution and antigen recognition of anti-nuclear antibodies in acute systemic lupus erythematosus. <i>Scientific Reports</i> , 2017, 7, 16428.	3.3	24
33	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2011, 21, 436-439.	1.8	23
34	Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2011, 21, 436-439.	1.8	22
35	Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab. <i>Rheumatology</i> , 2010, 49, 824-826.	1.9	21
36	Can IL-6 blockade rectify imbalance between Tregs and Th17 cells?. <i>Immunotherapy</i> , 2013, 5, 695-697.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Minimal influence of tocilizumab on IFN- $\gamma$ synthesis by tuberculosis antigens. <i>Modern Rheumatology</i> , 2010, 20, 130-133.	1.8	20
38	Adipocytokine Profile Reveals Resistin Forming a Prognostic-Related Cytokine Network in the Acute Phase of Sepsis. <i>Shock</i> , 2021, 56, 718-726.	2.1	17
39	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	1.8	15
40	Interleukin-6; pathogenesis and treatment of autoimmune inflammatory diseases. <i>Inflammation and Regeneration</i> , 2013, 33, 054-065.	3.7	13
41	Prompt Reduction in CRP, IL-6, IFN- $\gamma$ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838.	2.6	13
42	Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. <i>Scientific Reports</i> , 2022, 12, 8108.	3.3	13
43	Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab. <i>Modern Rheumatology</i> , 2011, 21, 420-422.	1.8	12
44	DNA Damage in Rheumatoid Arthritis: An Age-Dependent Increase in the Lipid Peroxidation-Derived DNA Adduct, Heptanone-Etheno-2-Deoxycytidine. <i>Autoimmune Diseases</i> , 2013, 2013, 1-8.	0.6	9
45	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	1.6	8
46	Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis. <i>Case Reports in Rheumatology</i> , 2012, 2012, 1-4.	0.6	7
47	IL-6 Superfamily. , 2017, , 573-586.		2
48	Interleukin-6 Inhibition in Inflammatory Diseases: Results Achieved and Tasks to Accomplish. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, S20-S28.	1.7	1
49	Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2105040118.	7.1	0